Open Government Portal

About this information

Open data is defined as structured data that is machine-readable, freely shared, used and built on without restrictions.

The key things to remember about open data are:

  • #Availability and access#: the data must be available as a whole and at no more than a reasonable reproduction cost, preferably by downloading over the internet. The data must also be available in a convenient and modifiable form.
  • #Re-use and redistribution#: the data must be provided under terms that permit re-use and redistribution including the intermixing with other datasets.
  • #Universal participation#: everyone must be able to use, re-use and redistribute. There should be no discrimination against fields of endeavour or against persons or groups. For example, 'non-commercial' restrictions that would prevent 'commercial' use, or restrictions of use for certain purposes (e.g. only in education), are not allowed.
47529 records

A Health Canada safety review was carried out as a follow-up assessment on the potential risk of retinal detachment with …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Oral FLUOROQUINOLONES assessing potential risk Retinal Detachment

In 2014, Health Canada completed a first safety review for the Omnipod because a high number of complaints, reporting high …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Omnipod Insulin Management-System assessing potential risk high-level of blood-sugar hyperglycemia

After becoming aware of international reports about neurological side effects, such as anxiety, panic reaction, visual hallucinations and seizures, possibly …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review MELATONIN N-acetyl-5-methoxytryptamine review of safety Melatonin-use in Children-and-Adolescents neurological side effects anxiety panic reaction visual hallucinations seizures

Health Canada carried out a safety review to investigate the potential risk of developing an abnormal heart rhythm (QT interval …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Loratadine Abnormal heart rhythm QT interval prolongation use of over-the-counter drug products

Health Canada carried out a safety review after learning that the European Medicines Agency was looking into a potential interaction …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Levetiracetam Methotrexate assessing potential risk Drug-Drug Interaction

Health Canada completed a safety review to evaluate if using digoxin was linked to a higher risk of death compared …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Lanoxin Toloxin Apo-digoxin PMS-digoxin Digoxin assessing potential higher risk risk of Death

Health Canada reviewed the potential risk of acute kidney injury with the use of levetiracetam, because of an article that …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review KEPPRA levetiracetam assessing potential risk Acute Kidney Injury Acute renal failure Interstitial nephritis

A safety review was carried out to evaluate the potential risk of Raynaud's phenomenon in patients taking Intuniv XR. Raynaud's …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review INTUNIV XR guanfacine hydrochloride assessing potential risk Raynaud's Phenomenon disorder of the blood vessels fingers and toes enough blood-and-oxygen lack of blood-and-oxygen pale skin bluish colour skin ...

As part of Health Canada's ongoing monitoring of glistening development in IOLs, Health Canada reviewed the available safety information related …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Intraocular lenses assessing potential risk small pockets liquid in intraocular-lenses glistening

A safety review was undertaken soon after the European Medicines Agency notified Health Canada of the possibility that the use …

Record Modified: May 9, 2024
Record Released: May 7, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Hydroxyzine ATARAX assessing potential risk abnormal heart rhythm abnormal changes electrical-activity of the-heart QT interval prolongation